These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29507500)

  • 1. Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA).
    Uccello M; Moschetta M; Mak G; Alam T; Henriquez CM; Arkenau HT
    Curr Oncol; 2018 Feb; 25(1):e90-e94. PubMed ID: 29507500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients.
    Kieler M; Unseld M; Bianconi D; Schindl M; Kornek GV; Scheithauer W; Prager GW
    J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32121198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
    Ur Rehman SS; Lim K; Wang-Gillam A
    Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
    Garcia G; Odaimi M
    J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer.
    Kieler M; Unseld M; Bianconi D; Prager GW
    Memo; 2017; 10(3):136-140. PubMed ID: 28989542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan.
    Furuse J
    J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31382681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives.
    Woo W; Carey ET; Choi M
    Onco Targets Ther; 2019; 12():1455-1463. PubMed ID: 30863113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line.
    Akhoundova Sanoyan D; Reiner CS; Papageorgiou P; Siebenhüner AR
    Case Rep Oncol; 2020; 13(1):79-84. PubMed ID: 32110224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
    Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
    Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study.
    Taieb J; Prager GW; Melisi D; Westphalen CB; D'Esquermes N; Ferreras A; Carrato A; Macarulla T
    ESMO Open; 2020 Jan; 5(1):. PubMed ID: 31958291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?
    Aprile G; Negri FV; Giuliani F; De Carlo E; Melisi D; Simionato F; Silvestris N; Brunetti O; Leone F; Marino D; Santini D; Dell'Aquila E; Zeppola T; Puzzoni M; Scartozzi M
    Crit Rev Oncol Hematol; 2017 Jul; 115():1-12. PubMed ID: 28602164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer.
    Martín AM; Hidalgo M; Alvarez R; Arrazubi V; Martínez-Galán J; Salgado M; Macarulla T; Carrato A
    J Cancer; 2018; 9(11):1978-1988. PubMed ID: 29896283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
    Rubinson DA; Wolpin BM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world.
    Pretta A; Spanu D; Mariani S; Liscia N; Ziranu P; Pusceddu V; Puzzoni M; Massa E; Scartozzi M; Lai E
    World J Clin Oncol; 2022 May; 13(5):417-422. PubMed ID: 35662988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving treatment landscape for early and advanced pancreatic cancer.
    Lau SC; Cheung WY
    World J Gastrointest Oncol; 2017 Jul; 9(7):281-292. PubMed ID: 28808501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
    Sonbol MB; Firwana B; Wang Z; Almader-Douglas D; Borad MJ; Makhoul I; Ramanathan RK; Ahn DH; Bekaii-Saab T
    Cancer; 2017 Dec; 123(23):4680-4686. PubMed ID: 28817187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive markers in pancreatic adenocarcinoma.
    Le N; Sund M; Vinci A;
    Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Management: Metastatic Disease.
    Ko AH
    Cancer J; 2017; 23(6):355-361. PubMed ID: 29189332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.